Abstract
Background Maternal respiratory syncytial virus (RSV) vaccine, RSV prefusion F protein vaccine (RSVpreF (Abrysvo®)), was found to be safe and efficacious in its phase III trial. However, post-hoc stratified analyses identified an excess of preterm births in the intervention arm in two upper middle-income countries, most prominently in South Africa. This study weighs the potential benefits and risks in mortality associated with maternal RSV vaccination in South Africa, assuming the increased risk of preterm births observed in the trial was caused by vaccination.
Methods and Findings We compared the estimated RSV-associated infant deaths averted by vaccination (benefits) and neonatal mortality potentially associated with vaccine-associated risk in preterm birth (risks) in South Africa. The benefit model estimated the South African RSV disease burden in 2011-16 and waning vaccine protection during infancy. The risk model estimated excess neonatal mortality using gestational age (GA)-specific mortality data from a South African cohort study and the GA-specific birth distribution in South Africa in the trial, but did not incorporate the mortality risk found in the vaccine trial in which no excess deaths occurred.
The benefit model estimated that vaccination would reduce RSV-associated infant deaths by 31 (95% Credible Interval (Crl): 27, 35) per 100,000 live births born to vaccinated mothers in South Africa. The risk model suggested that neonatal deaths would increase by 44 (95%CrI: −43, 210) with vaccination at 24-36 GA weeks, totaling 1.4 (95%CrI: −1.4, 7.0) excess neonatal deaths for every infant RSV death prevented. Using the data for infants born to mothers vaccinated at 27-36 GA weeks, the predicted risks sharply dropped and in 98% of the simulations the benefits outweighed the risks.
Conclusions If RSVpreF increases preterm birth risk, and if this increases neonatal mortality, then the benefit-risk analysis did not show that the direct benefits of vaccination in reducing RSV-associated infant mortality would substantially outweigh the risks of preterm birth-associated neonatal mortality in South Africa with vaccination from 24 GA weeks. There was large uncertainty in the analyses due to small numbers of preterm births. With vaccination from the third trimester, the benefit-risk analysis favoured vaccination.
Competing Interest Statement
SAM institution has received funding from Pfizer, GSK, MSD and AstraZeneca for research on RSV vaccines and RSV monoclonal antibodies. PB institution has received public-private partnership funding through the European Union IMI/IHI Respiratory Syncytial Virus Consortium in Europe (RESCEU) and Preparing for RSV immunisation and surveillance in Europe (PROMISE) projects (ceased in 2023). HJZ has received funding from Pfizer, MSD, and Sanofi for studies of RSV vaccines and monoclonal antibodies and serves on the Data Safety Management Board for Moderna RSV maternal vaccine and advisory boards to MSD and Pfizer.
Funding Statement
AM was funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology through the Doctoral Program for World-leading Innovative & Smart Education as part of the NU-LSHTM Joint PhD Programme for Global Health. AE is supported by the Japan Science and Technology Agency, Japan Society for the Promotion of Science, and Japan Agency for Medical Research and Development. SF is funded by the Einstein Foundation Berlin as an Einstein BUA Strategic Professor. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HJZ was funded by the Bill & Melinda Gates Foundation for the Drakenstein Child Health study. AM travel for collaborative visits for this project was supported by funding from Bill & Melinda Gates Foundation. MJ, SIL, and SRP were also supported by funding from Bill & Melinda Gates Foundation. This funder had roles in the study design, and data collection through its membership on the maternal RSV vaccine benefit-risk advisory group, but no role in data analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has received ethical approval from the London School of Hygiene & Tropical Medicine Ethics Committee (Ref: 29955).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- CFR
- case fatality rate
- CI
- confidence interval
- Crl
- credible interval
- DCHS
- the Drakenstein Child Health Study
- EMA
- European Medicines Agency
- FDA
- the US Food and Drug Administration
- GA
- gestational age
- LMIC
- low- and middle-income countries
- LRTI
- lower respiratory tract infection
- MCMC
- Markov chain Monte Carlo
- MA
- medically-attended
- RSV
- Respiratory syncytial virus
- RSVpreF
- RSV prefusion F protein vaccine
- SAGE
- Strategic Advisory Group of Experts on Immunization
- SARI
- severe acute respiratory illness
- VNMC
- the Vulnerable Newborn Measurement Collaboration
- WHO
- the World Health Organization
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos